Cargando…

miR-205-3p promotes lung cancer progression by targeting APBB2

Non-small cell lung cancer (NSCLC), a leading cause of cancer-associated mortality, has resulted in low survival rates and a high mortality worldwide. Accumulating evidence has suggested that microRNAs (miRs) play critical roles in the regulation of cancer progression and the present study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ling-Bin, Xiong, Jie, Zhang, Ya-Hui, Dai, Yun, Ren, Xiao-Ping, Ren, Ya-Juan, Han, Dong, Wei, Sheng-Hong, Qi, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222966/
https://www.ncbi.nlm.nih.gov/pubmed/34165160
http://dx.doi.org/10.3892/mmr.2021.12227
Descripción
Sumario:Non-small cell lung cancer (NSCLC), a leading cause of cancer-associated mortality, has resulted in low survival rates and a high mortality worldwide. Accumulating evidence has suggested that microRNAs (miRs) play critical roles in the regulation of cancer progression and the present study aimed to explore the underlying mechanism of miR-205 in NSCLC. Reverse transcription-quantitative PCR was performed, which determined that miR-205 expression was upregulated in NSCLC, and the present study detected the upregulation of miR-205-3p in a number of NSCLC cell lines and NSCLC tissues. In addition, the mediation of amyloid β precursor protein-binding family B member 2 (APBB2) by miR-205-3p was demonstrated. Moreover, miR-205-3p was predicted to directly target the 3′untranslated region of APBB2, which was confirmed using a dual-luciferase reporter assay. It was found that lentivirus mediated-APBB2 knockdown could promote cellular viability and suppress apoptosis in NSCLC cells, as determined via MTT, TUNEL and flow cytometry assays. Thus, the current findings highlighted the potential promotive impact of miR-205-3p on NSCLC processes and may provide theoretical evidence for miR-205-3p as a potential clinical gene therapy target.